Apalutamide Now Also Approved for Metastatic Prostate Cancer

ARTICLES

Apalutamide Now Also Approved for Metastatic Prostate Cancer

MEDSCAPE
PUBLISHED: 19 SEPTEMBER 2019

Last year, apalutamide (Erleada, Janssen) became the first drug to be approved in the United States for use in the treatment of nonmetastatic, castration-resistant prostate cancer. The approval marked the first time that the US Food and Drug Administration used metastasis-free survival as the primary endpoint in its decision making.